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FK 506-An Effective Immunosuppressant in Achieving Long-Term 
Functional Islet Allograft Survival in Diabetic Rats 
W.J. Tze, J. Tai, S.-S.C. Cheung, C. Ricardi, N. Murase, and T.E. Starzl 
TRANSPLANTED pancreatic islet tissue has been 
shown to restore normoglycemia and prevent the 
development of chronic complications in diabetic ani-
mals. 1 The application of allo- and xenotransplantation of 
pancreatic islets for the treatment of diabetes is hindered 
by immune rejection. FK 506, a new immunosuppressive 
agent, has been demonstrated to be effective in the pro-
longation of survival of heart, intestine, liver, and islet 
allografts in rats, and liver. kidney, and pancreas allografts 
in humans. 2-4 The efficacy of FK 506 in the prolongation of 
islet allograft survival has been found to be affected by the 
dosage of FK 506 and the site of the islet graft.3 The 
present study is aimed at achieving long-term functional 
rat islet allograft across major histocompatibility barrier 
using FK 506 as an immunosuppressant. 
MATERIALS AND METHODS 
Male rats of outbred Wistar (Wi) and inbred Lewis (Le) strains. 
with body weights of 350 to 500 g, were used as donors of 
pancreatic tissue. and rats of inbred ACI (RTI") strain were used 
as streptozotocin-induced (55 mglkg IV) diabetic recipients tHar-
Ian Sprague Dawley. Indianapolis. Ind). An animal is defined as 
diabetic only when serum glucose is greater than 400 mgldL over 
10 days. Pancreatic tissue was digested with collagenase. and the 
islets were handpicked under a dissection microscope. Contami-
nating acinar tissues and blood vessels were removed from the 
islets by the single-layer Hypaque-Ficoll separation technique.s 
For kidney subcapsular (KC) transplantation approximately 2.000 
freshly isolated islets, suspended in a total volume of 70 ILL 
Hanks' balanced salt solution (HBSS). were iqjected. For intra-
portal OPo) transplantation, the islets were suspended in 200 ILL 
HBSS in a Monoject U-lOO insulin syringe and injected over a 
I-minute period into diabetic recipients. The syringe was flushed 
twice with the recipients' blood. 
Iqjectable form of FK 506 (Lot 116393) was provided by 
Fujisawa Pharmaceutical Co (Osaka, Japan). The required 
amount of the compound was weighed out daily and prepared in 
saline within 10 minutes of 1M injection. The administration of FK 
506 was initiated on the day of transplantation. Protocol I con-
sisted of FK S06 at I mglkg/d 1M for 2 weeks. Protocol II 
consisted of FK 506 at 1 mglkg/d 1M for 2 weeks plus I mglkg/wk. 
Daily serum glucose and body weight of recipient rats were 
determined for 2 weeks after transplantation and then twice 
weekly thereafter. Rejection was considered to have occurred 
when the serum glucose level exceeded 200 mgldL on 3 succes-
sive days. Survival time for each recipient group is reported as 
mean:t SEM. 
Statistical evaluation was performed by Student's r test. IV 
glucose tolerance test (lVGTI, 1 glkg IV through femoral vein in 
overnight fasted animals) was performed in some islet recipients I 
week after the last dose of FK 506. Blood samples were collected 
from the tail at 0, I. 3. 5, 15. 30. 60. 90. and 120 minutes for 
glucose determination. Some functional grafts were removed for 
histologic and histochemical studies. Paraffin sections were 
stained for insulin and glucagon with immunoperoxidase staining 
(ABC Staining Kits. Vectastain. Cedarlane Laboratory. Hornby. 
Ontario) and frozen sections for ceHular markers with monoclonal 
antibodies (clones OX\. OX6, OX8. and W 3/25; Daymar Labo-
ratory. Toronto. Ontario). 
RESULTS 
Table 1 shows that fresh Wi islet allograft had a mean 
functional period of 7.4 ± 0.25 and 6.7 ± 0.5 days, 
respectively, when transplanted under the KC and IPo in 
diabetic ACI recipients. Diabetic ACI recipients of fresh 
Wi islets under the KC which received FK 506 1 mglkgld 
for 14 days had a much prolonged survival time. Seven of 
ten were rejected between 41 to 73 days following trans-
plantation, while the remaining three achieved survival of 
over 120 days. In diabetic rats transplanted with islets IPo 
and treated similarly with FK 506, seven of seven grafts 
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Table 1. Functional Period of WI Rat Islet Allograft Under the KC and IPo In Diabetic ACI Rata 
Group FK506 Site Survival (d) 
None KC 7.7,7.8,8 
2 None IPo 5,6.6.7.8,8 
3 1 mg/kgld 1M, day 0-13 KC 41,45.46,47.48.52.73. >120,* >122,t >124t 
4 1 mglkgld 1M. day 0-13: weekly thereafter KC >112.t >114.t >142. >145. >151, >152, >155. >160 
5 1 mg/kgld 1M. day 0-13 IPo >119, >120. >137. >150, >161. >163. >250 
'Died of aneslhesia; normal-appearing islets _e present at the graft site. 
tKkfney containing the islet alIogra1t was removed. 
Meen:!: SEM 
7.4:!:: 0.25 
6.7:!:: O.SO 
>72.8:!:: 11.1 
>141.4 :!:: 6.6 
>157.1 :t 16.9 
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Table 2. Functional Pertod of Mixed WI and La Strain Rat Islet 
Allograft Under the KC of Diabetic ACI Rsts 
Group 
1 
2 
FK 506 
None 
1 mglkgld 1M. day 
(H3; weekly thereaf· 
ter 
SUIVtYal (d) 
4.5.5.5.7 
67. 85. 90: 103. 
132 
Mean:t SEM 
5.2 ± 0.5 
>95.4 ± 10.8 
'Kidney contaming the islet allograft was removed and normaI-appearing islets 
were present at the graft arte. 
had prolonged survival. In the group given islet transplant 
under KC but treated with FK 506 at 1 mglkgld for 14 days 
followed by subsequent weekly injections. eight of eight 
recipients had prolonged functional islet allograft. Surgical 
removal of the kidney containing the allogeneic islet tissue 
resulted in the return to hyperglycemia in four of four 
recipients within 2 days. The body weight of the recipients 
remained constant during the FK 506 treatment period but 
increased when it was stopped or when changed to weekly 
injection. Following the surgical removal of the Wi islet 
graft. the body weight of the ACI recipients dropped 
rapidly. 
To assess the effect of FK 506 immunosuppression on 
the survival of islet allograft composed of tissue from two 
donor strains. diabetic ACI rats were transplanted under 
the KC with a mixture of Wi and Le strain islets. Table 2 
shows that the mixed strain islet allograft functioned for 
5.2 :±: 0.5 days (n = 5) in nonimmunosuppressed rats. FK 
506 treatment significantly prolonged the allograft function 
to >95.4 :±: IO.S days (n = 5). 
Figure I shows that the results of IVGrr performed in 
both groups of ACI recipients with functional Wi islets 
under KC. 1 week after the last injection of FK 506, were 
much improved over the diabetic controls. 
Insulin-containing islets were abundant under the KC of 
all the islet allograft recipients treated with FK 506. CD4 
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Fig 1. Serum glucose following IVGTT (1 g/kg body weight) in 
overnight fasted normal rats (\1--\1, n = 11), diabetic rats (<J--<J, n 
= 6), diabetic ACI recipient rats with functional islet allograft under 
KC treated with FK 506 (1 mg/kgld 1M. 2 weeks. 0--0, n=6; 1 
mglkg/d 1M, 2 weeks plus 1 mg/kg wk, 6.--6., n = 7) 1 week after 
the last FK 506 injection. 
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positive and CDS positive cells were present in the vicinity 
of the normal-appearing islets. However, they were not 
detected within the islets. 
DISCUSSION 
Results of the present study show that FK 506 is an 
effective immunosuppressant in prolonging fresh islet al-
lograft survival. At a daily dosage of I mglkg administered 
1M for 14 days, starting on the day of transplantation, 
significant prolongation of fresh Wi islet allograft survival 
was observed both under the KC and IPo. The efficacy of 
FK 506 is improved by additional weekly injection in the 
group with islets transplanted under KC. Furthermore, 
this treatment regimen was effective in prolonging islet 
allograft survival composed of tissues from two donor 
strains. This observation is important as islet tissue from 
more than one donor is needed to reverse the diabetic state 
of the recipients in clinical transplantation. 6 Though FK 
506 prolonged islet allograft from single and two donor 
strains transplanted under KC. the result achieved in the 
former group was significantly better. This may partly be 
explained by the higher immunogenicity of the islet prep-
aration used in the latter group. 
The present observation differed from that of Yasunami 
et al3 who failed to achieve prolonged islet allograft under 
KC. This difference could be due to the use of a higher 
dosage of FK 506 for a longer duration by us. Similar to 
their observation, we also observed the superiority of the 
IPo over the KC site in the islet transplantation model we 
have used. The suggestion that FK 506 is metabolized 
extensively in the liver before excretion may contribute to 
the superiority of the IPo site.7 
The islet allograft recipient animals had achieved nor-
malization of random blood glucose that was similar to that 
of normal controls. In addition. the glucose clearance rates 
were significantly improved. The mildly abnormal glucose 
tolerance found in these diabetic recipient animals could 
be attributed to one or more factors, including the non-
physiologic implant site, renal subcapsular space, and 
inadequate islet mass being used for transplantation. Since 
the IVGrr was performed 1 week following the comple-
tion of a 2-week course of FK 506 administration, the 
abnormality might also be partly due to the effect of FK 
506. Nalesnik et al8 earlier also observed a trend for FK 
506-treated rats to demonstrate higher levels of blood 
glucose than controls. 
Histologically, the islet graft from the recipients treated 
for a 14-day course of FK 506, plus weekly il\iection for 
over 100 days appeared normal and stained strongly posi-
tive for insulin. This would be in keeping with our finding 
of the effect of FK 506 on islets in vitro.9 
In conclusion, FK 506 is a potent, effective immunosup-
pressant in islet allograft transplantation in rats and has 
potential use for clinical islet transplantation in the treat-
ment of human diabetics. 
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